Результаты поиска - Martha Arellano

Отмена результатов
  1. 1
    Current advances in identification of cancer biomarkers in saliva

    Current advances in identification of cancer biomarkers in saliva по Martha Arellano

    Опубликовано 2009
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  2. 2
    Treatment of Relapsed Acute Leukemia after Allogeneic Transplantation: A Single Center Experience

    Treatment of Relapsed Acute Leukemia after Allogeneic Transplantation: A Single Center Experience по Martha Arellano, Amelia Langston, Elliott F. Winton, Christopher R. Flowers, Edmund K. Waller

    Опубликовано 2007
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  3. 3
    Identification of Tetranectin as a Potential Biomarker for Metastatic Oral Cancer

    Identification of Tetranectin as a Potential Biomarker for Metastatic Oral Cancer по Martha Arellano-Garcia, Roger Li, Xiaojun Liu, Yongming Xie, Xiaofei Yan, Joseph A. Loo, Shen Hu

    Опубликовано 2010
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  4. 4
    Identification of autoantibody biomarkers for primary Sjögren's syndrome using protein microarrays

    Identification of autoantibody biomarkers for primary Sjögren's syndrome using protein microarrays по Shen Hu, Arjan Vissink, Martha Arellano, Caroline Roozendaal, Hui Zhou, Cees G. M. Kallenberg, David T. Wong

    Опубликовано 2011
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  5. 5
    Salivary Proteomics for Oral Cancer Biomarker Discovery

    Salivary Proteomics for Oral Cancer Biomarker Discovery по Shen Hu, Martha Arellano, Pinmanee Boontheung, Jianghua Wang, Hui Zhou, Jiang Jiang, David Elashoff, Roger Wei, Joseph A. Loo, David T. Wong

    Опубликовано 2008
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  6. 6
    Preclinical validation of salivary biomarkers for primary Sjögren's syndrome

    Preclinical validation of salivary biomarkers for primary Sjögren's syndrome по Shen Hu, Kai Gao, Rodney Pollard, Martha Arellano-Garcia, Hui Zhou, Lei Zhang, David Elashoff, Cees G. M. Kallenberg, Arjan Vissink, David T. Wong

    Опубликовано 2010
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  7. 7
    Electrochemical Sensor for Multiplex Biomarkers Detection

    Electrochemical Sensor for Multiplex Biomarkers Detection по Wei Fang, Prabhudas S. Patel, Wei Liao, Kishore Chaudhry, Lei Zhang, Martha Arellano-Garcia, Shen Hu, David Elashoff, Hui Zhou, Shilin N. Shukla, Franky D. Shah, Chih‐Ming Ho, David T. Wong

    Опубликовано 2009
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  8. 8
    Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to antimalarial agent dihydroartemisinin

    Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to antimalarial agent dihydroartemisinin по Shannon Elf, Richard Z. Lin, Siyuan Xia, Yaozhu Pan, Changliang Shan, Shengjie Wu, Sagar Lonial, Manila Gaddh, Martha Arellano, H. Jean Khoury, Fadlo R. Khuri, Brendan Lee, Titus J. Boggon, Jun Fan, J Chen

    Опубликовано 2016
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  9. 9
    Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease

    Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease по H. Jean Khoury, Amelia Langston, Vamsi Kota, Jennifer A. Wilkinson, Iskra Pusic, Anand Jillella, Stephanie Bauer, Audrey S Kim, Danielle Roberts, Zaid Al‐Kadhimi, Imre Bodó, Elliott F. Winton, Martha Arellano, John F. DiPersio

    Опубликовано 2018
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  10. 10
    Safety and Efficacy of Menin Inhibition in Patients (Pts) with MLL-Rearranged and NPM1 Mutant Acute Leukemia: A Phase (Ph) 1, First-in-Human Study of SNDX-5613 (AUGMENT 101)

    Safety and Efficacy of Menin Inhibition in Patients (Pts) with MLL-Rearranged and NPM1 Mutant Acute Leukemia: A Phase (Ph) 1, First-in-Human Study of SNDX-5613 (AUGMENT 101) по Eytan M. Stein, Ibrahim Aldoss, John F. DiPersio, Richard M. Stone, Martha Arellano, Galit Rosen, Michael L. Meyers, Yifan Huang, Steve Smith, Rebecca G. Bagley, Michael J. Thirman, Manish R. Patel, Ghayas C. Issa

    Опубликовано 2021
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  11. 11
    A phase 1 dose‐escalation study of ARRY‐520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias

    A phase 1 dose‐escalation study of ARRY‐520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias по H. Jean Khoury, Guillermo Garcia‐Manero, Gautam Borthakur, Tapan Kadia, Maria Cielo Foudray, Martha Arellano, Amelia Langston, Beverly Bethelmie‐Bryan, Selena Rush, Kevin Litwiler, Sharon Karan, Heidi Simmons, Adam I. Marcus, Mieke Ptaszynski, Hagop M. Kantarjian

    Опубликовано 2011
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  12. 12
    Tyr-94 Phosphorylation Inhibits Pyruvate Dehydrogenase Phosphatase 1 and Promotes Tumor Growth

    Tyr-94 Phosphorylation Inhibits Pyruvate Dehydrogenase Phosphatase 1 and Promotes Tumor Growth по Changliang Shan, Hee‐Bum Kang, Shannon Elf, Jianxin Xie, Ting-Lei Gu, Mike Aguiar, Scott Lonning, Taro Hitosugi, Tae‐Wook Chung, Martha Arellano, H. Jean Khoury, Dong M. Shin, Fadlo R. Khuri, Titus J. Boggon, Jun Fan

    Опубликовано 2014
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  13. 13
    Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study

    Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study по Daniel A. Pollyea, Keith W. Pratz, Anthony Letai, Brian A. Jonas, Andrew H. Wei, Vinod Pullarkat, Marina Konopleva, Michael J. Thirman, Martha Arellano, Pamela S. Becker, Brenda Chyla, Wan‐Jen Hong, Qi Jiang, Jalaja Potluri, Courtney D. DiNardo

    Опубликовано 2020
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  14. 14
    Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors

    Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors по Hagop M. Kantarjian, Harry P. Erba, David F. Claxton, Martha Arellano, Roger M. Lyons, T.J. Kovascovics, Janice Gabrilove, Michael Craig, Dan Douer, Michael B. Maris, Stephen H. Petersdorf, Paul J. Shami, Andrew M. Yeager, Stephen Eckert, Rekha Abichandani, Stefan Faderl

    Опубликовано 2009
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  15. 15
    Tyr-301 Phosphorylation Inhibits Pyruvate Dehydrogenase by Blocking Substrate Binding and Promotes the Warburg Effect

    Tyr-301 Phosphorylation Inhibits Pyruvate Dehydrogenase by Blocking Substrate Binding and Promotes the Warburg Effect по Jun Fan, Hee‐Bum Kang, Changliang Shan, Shannon Elf, Ruiting Lin, Jianxin Xie, Ting‐Lei Gu, Mike Aguiar, Scott Lonning, Tae‐Wook Chung, Martha Arellano, H. Jean Khoury, Dong M. Shin, Fadlo R. Khuri, Titus J. Boggon, Sumin Kang, Jing Chen

    Опубликовано 2014
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  16. 16
    International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia

    International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia по Gail J. Roboz, Todd Rosenblat, Martha Arellano, Marco Gobbi, Jessica K. Altman, Pau Montesinos, Casey L. O’Connell, Scott R. Solomon, Arnaud Pigneux, Norbert Vey, Robert K. Hills, Tove Flem Jacobsen, Athos Gianella-Borradori, Øivind Foss, Sylvia Vetrhusand, Francis J. Giles

    Опубликовано 2014
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  17. 17
    Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

    Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia по Courtney D. DiNardo, Keith W. Pratz, Vinod Pullarkat, Brian A. Jonas, Martha Arellano, Pamela S. Becker, Olga Frankfurt, Marina Konopleva, Andrew H. Wei, Hagop M. Kantarjian, Tu Xu, Wan-Jen Hong, Brenda Chyla, Jalaja Potluri, Daniel A. Pollyea, Anthony Letai

    Опубликовано 2018
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  18. 18
    Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and <i>IDH1/2</i> Mutations

    Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and <i>IDH1/2</i> Mutations по Daniel A. Pollyea, Courtney D. DiNardo, Martha Arellano, Arnaud Pigneux, Walter Fiedler, Marina Konopleva, David A. Rizzieri, B. Douglas Smith, Atsushi Shinagawa, Roberto M. Lemoli, Monique Dail, Yinghui Duan, Brenda Chyla, Jalaja Potluri, Catherine L. Miller, Hagop M. Kantarjian

    Опубликовано 2022
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  19. 19
    Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study

    Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study по Hagop M. Kantarjian, Stefan Faderl, Guillermo Garcia‐Manero, Selina M. Luger, Parameswaran Venugopal, Lori J. Maness, Meir Wetzler, Steven Coutré, Wendy Stock, David F. Claxton, Stuart L. Goldberg, Martha Arellano, Stephen A. Strickland, Karen Seiter, Gary J. Schiller, Elias Jabbour, Judy H. Chiao, William Plunkett

    Опубликовано 2012
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  20. 20
    Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results

    Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results по Jorge E. Cortés, Benjamin D. Smith, Eunice S. Wang, Akil Merchant, Vivian G. Oehler, Martha Arellano, Daniel J. DeAngelo, Daniel A. Pollyea, Mikkael A. Sekeres, Tadeusz Robak, Weidong Wendy, Mirjana Zeremski, M. Naveed Shaik, A. Douglas Laird, Ashleigh O’Connell, Geoffrey Chan, Mark A. Schroeder

    Опубликовано 2018
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:

Инструменты поиска: